Beside strategies combining ICIs with other anti-tumor strategies i.e., conventional chemotherapy (reviewed in [273]), small-molecule inhibitors (reviewed in [274]), anti-angiogenic drugs and oncolytic viruses (both reviewed in [275]) and the already mentioned dual inhibition of immune checkpoints e.g., PD-1 and TIGIT, the efficacy of ICIs can also be improved by modulating the affinity of mAb to Fc receptors. Here, PDCD1 is linked to neoplasm.